Science and Pipeline
About INTASYL®
How INTASYL Works
Key Clinical Initiatives & Programs
PH-762 (PD-1 Protein Silencer)
- The neoadjuvant dose escalation study of intratumoral administration of PH-762 in adult patients with cutaneous squamous cell carcinoma, Stage IV melanoma, or Stage IV Merkel cell carcinoma. The trial is designed to evaluate the safety, assess tumor size, pharmacokinetics and biomarker analyses, and to determine the dose or dose range for continued study of PH-762.
- Learn more in Scientific Resources
- Learn more about the clinical trial.(NCT # 06014086)
PH-894 (BRD4 Protein Silencer)
PH-894, a member of the BET protein family, is a critical regulator of gen expression involved in cancer progression and metastasis. The primary challenge lies in precisely targeting BRD4, a task that has proven elusive for small molecule drug therapies that generate systemic toxicities, such as thrombocytopenia. PH-894 precisely silences only BRD4 offering the potential to reduce immune-related adverse events.
Learn more in Scientific Resources
Pipeline
Program
Discovery
Preclinical Proof
of Concept
IND Enabling
Studies
IND Clearance
Clinical Phase
PH-762
(PD-1 protein silencer)
Intratumoral Administration
Target Indications: Stages I, II, and IV cSCC, Stage IV Melanoma, and Stage IV Merkel cell carcinoma
Read More
Indications: Stages I, II, and IV cSCC, Stage IV Melanoma, and Stage IV Merkel cell carcinoma
PH-894
(BRD4 protein silencer)
Target Indications: Stage IV Melanoma, HNSCC, HCC, HPV-related c SCC
Intratumoral Administration
Read More
Indications: Stage IV Melanoma, HNSCC, HCC, HPV-related cSCC, cervical cancer
Synergies with Antibodies
Synergies with Cell Therapies
PH-894 is an INTASYL compound that silences BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.
Target(s) & Indication: BRD-4
Advanced Melanoma, Merkel Cell, HCC, TNBC
Scientific Resources
Investors
About us
Contact us
